Log in

NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Forecast & News

$54.00
+0.18 (+0.33 %)
(As of 02/17/2020 08:06 AM ET)
Today's Range
$53.26
Now: $54.00
$54.87
50-Day Range
$43.72
MA: $46.89
$54.03
52-Week Range
$42.48
Now: $54.00
$64.48
Volume420,722 shs
Average Volume536,755 shs
Market Capitalization$2.71 billion
P/E Ratio5.02
Dividend YieldN/A
Beta1.64
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.97 million
Book Value$12.27 per share

Profitability

Net Income$-29,400,000.00

Miscellaneous

Employees194
Market Cap$2.71 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.32) by $0.14. The biopharmaceutical company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.06 million. Arena Pharmaceuticals had a net margin of 68.29% and a return on equity of 42.34%. The firm's quarterly revenue was down 62.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) earnings per share. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

6 equities research analysts have issued 1-year price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $51.00 to $83.00. On average, they expect Arena Pharmaceuticals' stock price to reach $66.20 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

What is the consensus analysts' recommendation for Arena Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Arena Pharmaceuticals is focused on developing its two pipeline candidates — etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations and out-licensing of Belviq to focus on the pipeline is prudent in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in the market, due to competition." (12/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News stories about ARNA stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Arena Pharmaceuticals.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Cytokinetics (CYTK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), Exelixis (EXEL), NVIDIA (NVDA) and XOMA (XOMA).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (3.68%), FMR LLC (2.41%), Partner Fund Management L.P. (2.14%), Eagle Asset Management Inc. (1.88%), Alyeska Investment Group L.P. (1.53%) and Victory Capital Management Inc. (1.50%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., State Street Corp, Pictet Asset Management Ltd., Rafferty Asset Management LLC, UBS Group AG, Chartwell Investment Partners LLC, Russell Investments Group Ltd. and First Trust Advisors LP. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Insider Buying and Selling for Arena Pharmaceuticals.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Point72 Asset Management L.P., Alyeska Investment Group L.P., GW&K Investment Management LLC, Marshall Wace North America L.P., Rhenman & Partners Asset Management AB, Barclays PLC and Credit Suisse AG. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $54.00.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.71 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  821
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel